Proton Pump Inhibitor Use Is Not Strongly Associated With SARS-CoV-2 Related Outcomes: A Nationwide Study and Meta-analysis.
Proton Pump Inhibitor Use Is Not Strongly Associated With SARS-CoV-2 Related Outcomes: A Nationwide Study and Meta-analysis.
复制标题
质子泵抑制剂的使用与SARS-COV-2相关结果没有密切相关：全国研究和荟萃分析。
DOI：
10.1016/j.cgh.2021.05.011
复制
发表时间：
2021-09
期刊：
影响因子：
--
通讯作者：
Benfield T
中科院分区：
文献类型：
--
作者：
Israelsen SB;Ernst MT;Lundh A;Lundbo LF;Sandholdt H;Hallas J;Benfield T
质子泵抑制剂(PPI)的使用与严重急性呼吸综合征冠状病毒2(SARS-CoV-2)感染和严重后果的风险增加有关。然而，荟萃分析显示结果不明确，导致在正在进行的冠状病毒病2019(新冠肺炎)大流行期间使用购买力平价的安全性存在不确定性。我们进行了一项全国性的观察性研究，包括截至2020年12月1日丹麦的所有SARS-CoV-2病例(n=83,224例)。目前使用PPI与感染风险的关联在病例对照设计中进行了检验。我们调查了目前使用PPI的患者(n=4473)与从未使用过PPI的患者相比，发生严重后果的风险，包括机械通气、重症监护病房入院或死亡。采用倾向性评分匹配进行混杂对照。最后，我们对非典型肺炎冠状病毒2型感染风险和新冠肺炎死亡率进行了最新的荟萃分析。目前使用PPI与感染风险增加相关；调整后的优势比为1.08(95%可信区间[CI]，1.03-1.13)。在SARS-CoV-2病例中，使用PPI与住院风险增加相关；调整后的相对风险为1.13(1.03-1.24)，但与其他严重后果无关。最新的荟萃分析显示，PPI的使用与感染或死亡风险之间没有关联；合并优势比为1.00(95%可信区间，0.75-1.32)，相对风险为1.33(95%可信区间，0.71-2.48)。目前PPI的使用可能与SARS-CoV-2感染和住院的风险增加有关，但这些结果估计值最低限度地升高，最有可能受到残留混淆的影响。没有发现与严重后果有关的因素。荟萃分析的结果表明，当前的购买力平价指数对新冠肺炎的结果没有影响。
Proton pump inhibitor (PPI) use has been associated with increased risk of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and severe outcomes. However, meta-analyses show unclear results, leading to uncertainty regarding the safety of PPI use during the ongoing coronavirus disease 2019 (COVID-19) pandemic. We conducted a nationwide observational study including all SARS-CoV-2 cases (n = 83,224) in Denmark as of December 1, 2020. The association of current PPI use with risk of infection was examined in a case-control design. We investigated the risk of severe outcomes, including mechanical ventilation, intensive care unit admission, or death, in current PPI users (n = 4473) compared with never users. Propensity score matching was applied to control for confounding. Finally, we performed an updated meta-analysis on risk of SARS-CoV-2 infection and COVID-19 mortality attributable to PPI use. Current PPI use was associated with increased risk of infection; adjusted odds ratio, 1.08 (95% confidence interval [CI], 1.03–1.13). Among SARS-CoV-2 cases, PPI use was associated with increased risk of hospital admission; adjusted relative risk, 1.13 (1.03–1.24), but not with other severe outcomes. The updated meta-analysis showed no association between PPI use and risk of infection or mortality; pooled odds ratio, 1.00 (95% CI, 0.75–1.32) and relative risk, 1.33 (95% CI, 0.71–2.48). Current PPI use may be associated with an increased risk of SARS-CoV-2 infection and hospital admission, but these results with minimally elevated estimates are most likely subject to residual confounding. No association was found for severe outcomes. The results from the meta-analysis indicated no impact of current PPI use on COVID-19 outcomes.
登录
查看更多内容
影响因子：
3.1
作者：
Darnell ME;Subbarao K;Feinstone SM;Taylor DR
通讯作者：
Taylor DR
影响因子：
3.7
作者：
Lambert, Allison A.;Lam, Jennifer O.;Crowell, Trevor A.
通讯作者：
Crowell, Trevor A.
影响因子：
2.8
作者：
Vila-Corcoles, Angel;Satue-Gracia, Eva;Basora-Gallisa, Josep
通讯作者：
Basora-Gallisa, Josep
影响因子：
120.7
作者：
Herzig, Shoshana J.;Howell, Michael D.;Marcantonio, Edward R.
通讯作者：
Marcantonio, Edward R.
DOI：
10.1016/j.cgh.2020.09.041
发表时间：
2021-07
期刊：
Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
影响因子：
--
作者：
Elmunzer BJ;Spitzer RL;Foster LD;Merchant AA;Howard EF;Patel VA;West MK;Qayed E;Nustas R;Zakaria A;Piper MS;Taylor JR;Jaza L;Forbes N;Chau M;Lara LF;Papachristou GI;Volk ML;Hilson LG;Zhou S;Kushnir VM;Lenyo AM;McLeod CG;Amin S;Kuftinec GN;Yadav D;Fox C;Kolb JM;Pawa S;Pawa R;Canakis A;Huang C;Jamil LH;Aneese AM;Glamour BK;Smith ZL;Hanley KA;Wood J;Patel HK;Shah JN;Agarunov E;Sethi A;Fogel EL;McNulty G;Haseeb A;Trieu JA;Dixon RE;Yang JY;Mendelsohn RB;Calo D;Aroniadis OC;LaComb JF;Scheiman JM;Sauer BG;Dang DT;Piraka CR;Shah ED;Pohl H;Tierney WM;Mitchell S;Condon A;Lenhart A;Dua KS;Kanagala VS;Kamal A;Singh VK;Pinto-Sanchez MI;Hutchinson JM;Kwon RS;Korsnes SJ;Singh H;Solati Z;Willingham FF;Yachimski PS;Conwell DL;Mosier E;Azab M;Patel A;Buxbaum J;Wani S;Chak A;Hosmer AE;Keswani RN;DiMaio CJ;Bronze MS;Muthusamy R;Canto MI;Gjeorgjievski VM;Imam Z;Odish F;Edhi AI;Orosey M;Tiwari A;Patwardhan S;Brown NG;Patel AA;Ordiah CO;Sloan IP;Cruz L;Koza CL;Okafor U;Hollander T;Furey N;Reykhart O;Zbib NH;Damianos JA;Esteban J;Hajidiacos N;Saul M;Mays M;Anderson G;Wood K;Mathews L;Diakova G;Caisse M;Wakefield L;Nitchie H;Waljee AK;Tang W;Zhang Y;Zhu J;Deshpande AR;Rockey DC;Alford TB;Durkalski V;North American Alliance for the Study of Digestive Manifestations of COVID-19
通讯作者：
North American Alliance for the Study of Digestive Manifestations of COVID-19